Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reply to Letter to the Editor regarding "Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement".

American heart journal·2013

Same author

Comparison of adverse outcomes after contemporary percutaneous coronary intervention in women versus men with acute coronary syndrome.

The American journal of cardiology·2013

Same author

Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2013

Same author

Outcome improvement for STEMI patients: the next breakthrough in interventional cardiology?

Cardiovascular revascularization medicine : including molecular interventions·2013

Same author

Graft-free surgical retroperitoneal vascular access as bail-out technique for failed percutaneous approach to transcatheter aortic valve replacement.

Cardiovascular revascularization medicine : including molecular interventions·2013

Same author

Comparison of long-term outcomes between everolimus-eluting and sirolimus-eluting stents in small vessels.

The American journal of cardiology·2013

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Drug-eluting stent safety.

Tina L Pinto Slottow¹, Ron Waksman

¹Division of Cardiology, Washington Hospital Center, Washington, District of Columbia 20010, USA.

The American Journal of Cardiology

|November 21, 2007

Summary

Drug-eluting stents (DESs) reduce repeat procedures for in-stent restenosis after percutaneous coronary intervention (PCI). However, DESs raise safety concerns regarding stent thrombosis and other complications.

Area of Science:

Cardiovascular Medicine
Interventional Cardiology
Biomaterials Science

Background:

Drug-eluting stents (DESs) were developed to prevent in-stent restenosis following percutaneous coronary intervention (PCI).
Widespread adoption of DESs occurred due to their perceived benefit in reducing restenosis rates.

Purpose of the Study:

To review the safety issues associated with drug-eluting stents (DESs).
To evaluate the contemporary concerns regarding DES use in PCI, particularly stent thrombosis.

Main Methods:

Review of published literature on drug-eluting stent safety.
Analysis of outcomes data comparing DESs with bare metal stents.
Examination of mechanisms contributing to DES-related complications.

Related Experiment Videos

Last Updated: Jul 10, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Main Results:

DESs have decreased repeat procedures for in-stent restenosis but have not improved hard endpoints like death or myocardial infarction.
Stent thrombosis, especially very late stent thrombosis (>1 year post-PCI), remains a concern with DESs.
Other reported issues include late-acquired incomplete stent apposition and abnormal endothelial function.

Conclusions:

While DESs effectively reduce restenosis, their long-term safety profile requires careful consideration.
Ongoing surveillance for stent thrombosis and other adverse events is crucial for patients undergoing PCI with DESs.
Further research is needed to fully understand and mitigate the risks associated with DES implantation.